Adalimumab News and Research

RSS
Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.
Two equally effective TNF inhibitors in rheumatoid arthritis

Two equally effective TNF inhibitors in rheumatoid arthritis

MusculoskeletalNetwork features special coverage of sessions from ACR annual meeting

MusculoskeletalNetwork features special coverage of sessions from ACR annual meeting

Preeclampsia risk higher for women with Lupus

Preeclampsia risk higher for women with Lupus

BioXpress, AET BioTech enter agreement to co-develop Adalimumab biosimilar

BioXpress, AET BioTech enter agreement to co-develop Adalimumab biosimilar

Carotid ultrasound improves risk management in rheumatoid arthritis

Carotid ultrasound improves risk management in rheumatoid arthritis

Abbott announces results from HUMIRA clinical studies on ulcerative colitis

Abbott announces results from HUMIRA clinical studies on ulcerative colitis

Rheumatoid arthritis treatment foiled by gum disease

Rheumatoid arthritis treatment foiled by gum disease

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott receives FDA approval for Humira to treat ulcerative colitis

Abbott receives FDA approval for Humira to treat ulcerative colitis

Early, intensive therapy with adalimumab can help treat rheumatoid arthritis

Early, intensive therapy with adalimumab can help treat rheumatoid arthritis

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

'No malignancy risk' with biologic response modifiers

'No malignancy risk' with biologic response modifiers

Tofacitinib efficacy suggested for rheumatoid arthritis

Tofacitinib efficacy suggested for rheumatoid arthritis

Study compares mortality rates among RA patients treated with individual TNF inhibitors

Study compares mortality rates among RA patients treated with individual TNF inhibitors

Adalimumab effective in maintaining remission in pediatric patients with Crohn's disease

Adalimumab effective in maintaining remission in pediatric patients with Crohn's disease

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

Psoriasis TNF-α therapeutic effects mediated by MSC antioxidant reduction

Psoriasis TNF-α therapeutic effects mediated by MSC antioxidant reduction

Anti-TNFs increase risk for herpes zoster infections in IRD patients

Anti-TNFs increase risk for herpes zoster infections in IRD patients

Data from abatacept versus adalimumab Phase IIIb comparison study on RA

Data from abatacept versus adalimumab Phase IIIb comparison study on RA

Anti-TNFs increase risk of shingles in patients with inflammatory rheumatic diseases

Anti-TNFs increase risk of shingles in patients with inflammatory rheumatic diseases